Takeda announces positive results in phase 2b study of investigational tak-279, an oral, once-daily tyk2 inhibitor, in people with moderate-to-severe plaque psoriasis

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive results from a phase 2b clinical trial of tak-279 (ndi-034858), a highly selective, oral allosteric tyrosine kinase 2 (tyk2) inhibitor, in patients with moderate-to-severe plaque psoriasis.
TAK Ratings Summary
TAK Quant Ranking